Collegium Pharmaceutical, Inc.
Income Statement
| Line Item | FY2017 | FY2016 |
|---|---|---|
| Revenue | $28.5M | $1.7M |
| Cost of Revenue | $2.6M | $213.0K |
| Gross Profit | $25.9M | $1.5M |
| Gross Margin | 90.9% | 87.6% |
| Operating Expenses | ||
| Research & Development | $8.6M | $14.9M |
| SG&A Expense | $92.8M | $80.6M |
| Operating Income | $-75.4M | $-94.1M |
| Operating Margin | -264.9% | -5,498.7% |
| Interest Expense | — | $94.0K |
| Pretax Income | — | — |
| Income Tax Expense | — | — |
| Net Income | $-74.9M | $-94.2M |
| Net Margin | -262.9% | -5,504.1% |
| EPS (Basic) | $-2.47 | $-3.88 |
| EPS (Diluted) | $-2.47 | $-3.88 |
| Shares Outstanding (Basic) | 32.8M | 29.4M |
| Shares Outstanding (Diluted) | 32.8M | 29.4M |
| Dividends Per Share | — | — |